Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Hurdle technology in fruit processing.

Gómez PL, Welti-Chanes J, Alzamora SM.

Annu Rev Food Sci Technol. 2011;2:447-65. doi: 10.1146/annurev-food-022510-133619. Review.

PMID:
22129391
2.

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.

Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS; VRC 301 Study Team.

Vaccine. 2008 Nov 25;26(50):6338-43. doi: 10.1016/j.vaccine.2008.09.026. Epub 2008 Sep 26.

3.

A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.

Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS.

J Infect Dis. 2007 Dec 15;196(12):1732-40. doi: 10.1086/523650.

4.

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.

Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS; VRC 007 Study Team.

Vaccine. 2007 May 16;25(20):4085-92. Epub 2007 Mar 7.

PMID:
17391815
5.

Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.

Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, Gomez PL, Andrews CA, Koup RA, Bailer RT, Stein JA, Roederer M, Nabel GJ, Graham BS.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):601-5.

6.

Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells.

Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ.

PLoS Pathog. 2007 Feb;3(2):e25.

7.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ; Vaccine Research Center 004 Study Team.

J Infect Dis. 2006 Dec 15;194(12):1650-60. Epub 2006 Nov 8.

8.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS; Vaccine Research Center 006 Study Team.

J Infect Dis. 2006 Dec 15;194(12):1638-49. Epub 2006 Nov 8. Erratum in: J Infect Dis. 2009 Oct 15;200(8):1352-3.

9.

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS.

Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. Epub 2006 Sep 20.

10.

Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts.

Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL.

Toxicol Sci. 2006 Jun;91(2):610-9. Epub 2006 Mar 28.

11.
12.

Uric acid metabolism in psoriasis.

Puig JG, Mateos FA, Jiménez ML, Gomez PL, Michán AA, Vázquez JO.

Adv Exp Med Biol. 1986;195 Pt A:411-6. No abstract available.

PMID:
3728171
13.

Effect of glipentide on galactose absorption and disaccharidase activity in rat small intestine.

Gómez PL, Planas JM, Moretó M, Bolufer J.

Rev Esp Fisiol. 1980 Dec;36(4):445-8.

PMID:
7221166

Supplemental Content

Loading ...
Support Center